文献速递肝病

终末期肝病模型-乳酸评分与乳酸清除率在合并脓毒的危重肝硬化患者中的应用

Model for End-Stage Liver Disease-Lactate and Lactate Clearance in Critically Ill Cirrhosis Patients With Sepsis.
PubMed 文献 · Am J Gastroenterol · 2026-01-27

该研究基于美国20家医院2014-2022年3879例ICU肝硬化合并脓毒症患者,评估MELD-LA评分与24小时乳酸清除率对30天死亡的预测价值,并在亚太31中心1259例队列中外部验证。结果显示24小时内乳酸清除≥35%与30天生存改善独立相关,北美OR 0.41(95%CI 0.31-0.53,P<0.001),亚太OR 0.42(95%CI 0.28-0.62,P<0.001)。

要点

  • ICU肝硬化合并脓毒症患者24小时乳酸清除≥35%与30天死亡风险降低相关。
  • MELD-LA与乳酸清除率联合可早期进行风险分层并评估治疗反应。
  • 乳酸清除≥35%组早期抗生素使用比例高于清除<10%组(82.5% vs 67.6%,P<0.001)。

核心结论

  • 早期乳酸清除≥35%可预测ICU肝硬化合并脓毒症患者30天生存改善,联合MELD-LA有助于风险分层。

研究设计与样本

  • 回顾性队列研究,北美20家医院2014-2022年3879例ICU肝硬化合并脓毒症患者,并在亚太31中心2009-2019年1259例队列中外部验证。

主要发现

  • 北美队列中乳酸清除≥35%与30天生存改善相关(OR 0.41,95%CI 0.31-0.53,P<0.001)。
  • 亚太队列中乳酸清除≥35%与死亡风险降低60%相关(OR 0.42,95%CI 0.28-0.62,P<0.001)。
  • 存活者乳酸中位变化为-1.04(清除35%),非存活者为-0.4(清除12%)。
  • 乳酸清除≥35%组早期抗生素使用比例高于清除<10%组(82.5% vs 67.6%,P<0.001)。

关键数值与推荐

  • 24小时内乳酸清除≥35%作为改善30天生存的预测阈值。
  • 北美队列OR 0.41(95%CI 0.31-0.53,P<0.001);亚太队列OR 0.42(95%CI 0.28-0.62,P<0.001)。

临床怎么用

  • 对ICU肝硬化合并脓毒症患者,可动态监测MELD-LA与24小时乳酸清除率以早期风险分层。
  • 乳酸清除≥35%提示治疗反应良好,可据此评估复苏与抗感染治疗的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A Model for End-Stage Liver Disease-lactate (MELD-LA) score is an independent predictor of inpatient mortality and organ failure validated in more than 8,600 patients across diverse settings. However, its utility in sepsis, particularly when combined with lactate clearance (LA clearance), has not been fully evaluated. In this study, we examined the dynamic role of MELD-LA with 24-hour LA clearance as a predictor of 30-day mortality in critically ill patients with cirrhosis and sepsis. METHODS: We analyzed cirrhosis patients with sepsis admitted to the intensive care unit (ICU) in a large US healthcare system (20 hospitals) from 2014 to 2022, examining MELD-LA and LA clearance within 24 hours as predictors of 30-day mortality. We externally validated our findings in the Asian Pacific Association for the Study of the Liver-acute-on-chronic liver failure Research Consortium, a multinational Asian cohort (31 centers) from 2009 to 2019. RESULTS: A total of 3,879 cirrhosis patients with sepsis were admitted to the ICU (43.2% female, 20.5% Hispanic, 12.4% on dialysis; mean initial LA 4.5 mmol/L, MELD 20.8, MELD-LA 17.6). Survivors showed a median lactate change of -1.04 (35% clearance) compared with -0.4 (12%) for nonsurvivors. LA clearance within 24 hours was influenced by the presenting MELD-LA. In the North American cohort, ≥35% LA clearance was associated with improved 30-day survival (odds ratio 0.41, 95% CI 0.31-0.53; P < 0.001). Similarly, in the Asian Pacific Association for the Study of the Liver cohort (n = 1,259), ≥35% clearance was linked to a 60% reduction in mortality (odds ratio 0.42, 95% CI 0.28-0.62; P < 0.001). When stratified by LA clearance, patients with LA clearance of ≥35% had a higher percentage of early administration of resuscitative measures than those with LA clearance of < 10% especially regarding early antibiotic administration (82.5% vs 67.6%; P value <0.001). DISCUSSION: Early reduction in initial LA by one-third predicts 30-day mortality and may indicate treatment response in cirrhosis patients with sepsis in the ICU. Combining MELD-LA and LA clearance early enables better risk stratification and informs management.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shabbir R, Garrido-Trevino L, O'Leary JG, et al. Model for End-Stage Liver Disease-Lactate and Lactate Clearance in Critically Ill Cirrhosis Patients With Sepsis. Am J Gastroenterol. 2026. PMID: 41589697. doi:10.14309/ajg.0000000000003934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。